New Clinical Pharmacology Executive Joins West Coast Clinical Trials, Inc.
Published: Sep 09, 2011
Mel Affrime comes with a wealth of experience within the industry, having spent the last five years at ICON Development Solutions as Chief Scientific Officer where he built an excellent reputation for delivering cutting edge translational medicine drug development programs for numerous clients.
“I am excited to start a new chapter in my career with West Coast Clinical Trials, LLC and look forward to working with the team to further develop their already extensive service suite,” said Affrime. “I am fortunate to be joining such a respected company that prides itself on top quality service.”
As former Vice President and Global Head of Profiling Clinical Pharmacology at Novartis Pharmaceuticals and former Vice President, Clinical Research and GCP Compliance at Schering Plough, he was responsible for the Global Early Development programs in a wide range of therapeutic areas. He has spent twenty-four years in the Global Pharmaceutical Industry.
“Affrime’s wealth of experience and industry knowledge has already made him a key addition to the WCCT family. We view his appointment as a sign of our commitment to being the leading company in our industry. There is increasing demand from our customers to design phase 1 studies with multiple endpoints and integrate development plans with a global focus,” said Kenneth Kim, MD, CEO of WCCT. “This led us to look for an addition to our team who will fit in with our ethos of innovation and exceptional service, and we feel quite fortunate that we were able to find someone of Affrime’s caliber who will help our clients develop cutting edge phase 1 development programs. I am confident that Affrime will play a key role in providing and implementing high quality and innovative research solutions for our clients.”
WCCT is a privately owned early phase development contract research organization, conveniently located near 3 major airports in Southern California. WCCT was founded by Dr. Kenneth Kim who is board certified in Internal Medicine and Allergy and Immunology. Conducting trials since 1998, WCCT has been audited by the FDA and numerous pharmaceutical and biotechnology companies. WCCT’s location and access to an ethnically diverse population allows for a wide variety of study designs including ethnic bridging. With 150 beds in two locations and over 60,000 square feet, a well-trained and experienced staff, and advanced technological procedures, WCCT brings the highest quality to the pharmaceutical and biotechnology industries. (www.wcct.com)
West Coast Clinical Trials, LLC
Business Development 1-714.252.0783